ALN-TTRSC (revusiran)
ALN-TTRSC-001
Phase 1 small_molecule completed
Quick answer
ALN-TTRSC (revusiran) for TTR-mediated Amyloidosis is a Phase 1 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- TTR-mediated Amyloidosis
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed